Merck to build out immunology presence with $11 billion Prom

Merck & Co said on Sunday
it will buy Prometheus Biosciences Inc for about $10.8
billion, picking up a promising experimental treatment for
ulcerative colitis and Crohn's disease and building up... | April 16, 2023

Related Keywords

New Jersey , United States , California , Bengaluru , Karnataka , India , Akanksha Khushi , David Goodman , Tom Hogue , Robert Davis , Kanjyik Ghosh , Seagen Inc , Merck Co , Pfizer Inc , Reuters , Prometheus Biosciences Inc , Chief Executive Robert Davis , Wall Street , Michael Erman , Bill Berkrot , Prometheus Biosciences , Nc Stock Exchange , News , Information , Press Release , Merck , O , Aid , N , Hill , Guy , Prometheus , Iosciences , Nc , Or , Bout , Ticking , P , Romising , Experimental , Treatment , Colitis , End , Disease , Uilding Rxdx Us74349u1088 ,